Press Releases
June 22, 2021
Tempest and Millendo Announce Stockholder Approval of Merger
May 27, 2021
Tempest Therapeutics to Present at the Jefferies Healthcare Conference
March 29, 2021
Tempest and Millendo Announce Proposed Merger Agreement
January 7, 2021
Tempest Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 8, 2021
Tempest Therapeutics to Present at the H.C. Wainwright Virtual Bioconnect Conference
October 21, 2020
Sam Whiting, M.D., Ph.D., Joins Tempest as Executive Vice President and Chief Medical Officer
July 31, 2020
Tempest Therapeutics to Present at Two Investor Conferences in August
February 24, 2020
Tempest Therapeutics to Present at 9th Annual SVB Leerink Global Healthcare Conference
January 30, 2020
Tempest Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPST-1495 and Welcomes New Investors
November 8, 2019
Tempest Therapeutics’ Oncology Programs Presented at Society of Immunotherapy for Cancer Annual Meeting
October 7, 2019
Tempest Therapeutics Names Biopharmaceutical Executive Stephen Brady As President and Chief Operating Officer
October 2, 2019
Tempest Therapeutics Announces Multiple Presentations at Upcoming SITC 34th Annual Meeting
May 16, 2019
Tempest Therapeutics Starts Phase I/Ib Clinical Trial with First-In-Class PPAR Alpha Antagonist
November 13, 2018
Tempest Therapeutics Reports Proof of Mechanism Data for First‐In‐Class PPAR Alpha Antagonist
March 28, 2018
Tempest Therapeutics Closes $70 Million Series B Financing